Skip to main content
Equibles
ALT logo

ALT · Altimmune, Inc.

Track ALT — free

Use ALT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ALT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.94 +0.06 (+2.08%) At close · Aug 14
Market Cap
$571.88M
Shares
194.52M

Altimmune, Inc. Earnings Call Transcripts

Every quarterly earnings call for Altimmune, Inc. (ALT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼98.7% $2,000 −$23.52M '22 Q3 22-11-10 ▼103.4% $ −$21.66M '22 Q4 23-02-28 ▼34.4% $21,000 −$20.07M '23 Q1 23-05-11 ▼25% $6,000 −$16.06M '23 Q2 23-08-10 ▲18000% $362,000 −$20.67M '23 Q3 23-11-07 · $37,000 −$31.64M '23 Q4 24-03-27 ▼76.2% $5,000 −$24.39M '24 Q1 24-05-09 ▼16.7% $5,000 −$24.64M '24 Q2 24-08-08 ▼98.6% $5,000 −$22.84M '24 Q3 24-11-12 ▼86.5% $5,000 −$23.18M '24 Q4 25-02-27 ▲0% $5,000 −$19.57M '25 Q1 25-05-13 ▲0% $5,000 −$22.15M '25 Q2 25-08-12 ▲0% $5,000 −$19.01M '25 Q3 25-11-06 LATEST ▲420% $26,000 −$27.36M '25 Q4 26-03-05
Earnings call
FY26 · Q2
2026-08-12
RECLAIM Phase 2 Trial in AUD Topline Results Conference Call
Diluted EPS
$-0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-10
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-04
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-13
Altimmune, Inc. Q1 FY2026 Earnings Call
Confident tone Pemvidutide / MASH (PERFORMA Phase III) lead program Liver biopsy / diagnostic approaches in Phase III Phase II IMPACT 48-week data and EASL presentation
Diluted EPS
$-0.18
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Altimmune, Inc. Q4 FY2025 Earnings Call
Confident tone PEMB Phase III NASH program planning and FDA engagement Phase II ALD trial enrollment Phase II AUD trial readout timing
Revenue
$26,000*
▲ 420% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Altimmune, Inc. Q3 FY2025 Earnings Call
Confident tone MASH / IMPACT trial and pemvidutide efficacy FDA end-of-Phase II meeting and Phase III preparation Alcohol use disorder (AUD) / RECLAIM trial
Revenue
$5,000
▲ 0% YoY
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Altimmune, Inc. Q2 FY2025 Earnings Call
Confident tone Pipeline expansion - AUD and ALD Phase III planning and FDA interactions NASH / IMPACT Phase II results
Revenue
$5,000
▲ 0% YoY
Diluted EPS
$-0.27
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Altimmune, Inc. Q1 FY2025 Earnings Call
Confident tone IMPACT Phase 2b MASH/NASH readout Pemvidutide liver fat and weight loss profile Phase 3 NASH planning and FDA interactions
Revenue
$5,000
▲ 0% YoY
Diluted EPS
$-0.26
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Altimmune, Inc. Q4 FY2024 Earnings Call
Confident tone IMPACT Phase 2b MASH readout Phase 3 and regulatory planning Pipeline expansion to additional indications
Revenue
$5,000*
▼ 86.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Altimmune, Inc. Q3 FY2024 Earnings Call
Confident tone Additional Indications Expansion MASH / IMPACT Phase 2b Trial Obesity / Phase 3 Velocity Program
Revenue
$5,000
▼ 98.6% YoY
Diluted EPS
$-0.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Altimmune, Inc. Q2 FY2024 Earnings Call
Revenue
$5,000
▼ 16.7% YoY
Diluted EPS
$-0.35
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Altimmune, Inc. Q1 FY2024 Earnings Call
Confident tone Pemvidutide obesity program and MOMENTUM data MASH / IMPACT Phase 2b trial Partnering strategy for pemvidutide
Revenue
$5,000
▼ 76.2% YoY
Diluted EPS
$-0.34
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-27
Altimmune, Inc. Q4 FY2023 Earnings Call
Confident tone MOMENTUM Phase II obesity trial results IMPACT Phase IIb MASH trial Body composition and lean mass preservation
Revenue
$37,000*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Altimmune, Inc. Q3 FY2023 Earnings Call
Revenue
$362,000
▲ 18000% YoY
Diluted EPS
$-0.39
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Altimmune, Inc. Q2 FY2023 Earnings Call
Revenue
$6,000
▼ 25% YoY
Diluted EPS
$-0.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Altimmune, Inc. Q1 FY2023 Earnings Call
Revenue
$21,000
▼ 34.4% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Altimmune, Inc. Q4 FY2022 Earnings Call
Revenue
$*
▼ 103.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Altimmune, Inc. Q3 FY2022 Earnings Call
Revenue
$2,000
▼ 98.7% YoY
Diluted EPS
$-0.48
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Altimmune, Inc. Q2 FY2022 Earnings Call
Revenue
$8,000
▼ 94.2% YoY
Diluted EPS
$-0.42
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Altimmune, Inc. Q1 FY2022 Earnings Call
Revenue
$32,000
▼ 96.2% YoY
Diluted EPS
$-0.44
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-15
Altimmune, Inc. Q4 FY2021 Earnings Call
Revenue
$3.28M*
▲ 41.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Altimmune, Inc. Q3 FY2021 Earnings Call
Revenue
$158,000
▼ 94.6% YoY
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Altimmune, Inc. Q2 FY2021 Earnings Call
Revenue
$137,000
▼ 81% YoY
Diluted EPS
$-0.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-17
Altimmune, Inc. Q1 FY2021 Earnings Call
Revenue
$838,000
▼ 62.1% YoY
Diluted EPS
$-0.38
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Altimmune, Inc. Q4 FY2020 Earnings Call
Revenue
$2.31M*
▲ 301.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Altimmune, Inc. Q3 FY2020 Earnings Call
Revenue
$2.94M
▲ 356.2% YoY
Diluted EPS
$-0.54
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-16
Altimmune, Inc. Q2 FY2020 Earnings Call
Revenue
$721,636
▼ 55.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-13
Altimmune, Inc. Q1 FY2020 Earnings Call
Revenue
$2.21M
▼ 25.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-27
Altimmune, Inc. Q4 FY2019 Earnings Call
Revenue
$575,802*
▼ 77.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–29 of 29 earnings calls
Key facts CIK 1326190 CUSIP 02155H200 13F (30d) 201 filings 199 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)